• Science Saturday: Biomanufacturing 101 — Understanding a new era of therapeutics

manufacturing at the Regenerative Medicine Biotrust

Advancing cellular discoveries from clinical trials to commercial therapy is a cornerstone of Mayo Clinic's strategic emphasis on biomanufacturing. The long-term vision is to provide new cures for patients with unmet needs.

"Biomanufacturing is a type of manufacturing that utilizes sources from the human body — cells, blood, enzymes, tissues, genes or genetically engineered cells for use in medicines. We call these biologics," says Julie Allickson, Ph.D., the Michael S. and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics. "Biologics become a living drug within the body aimed at continually healing damaged tissues and cells." Dr. Allickson is also the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Medicine.

Biomanufacturing next-generation drugs

Biomanufacturing could usher in a new era of biologically based medicines that show hope of going beyond available complex molecule-based drugs to treat illness.

These next-generation biotherapeutics derived from living organisms show potential to:

  • Target specific cells or tissues needing repair.
  • Trigger fewer adverse effects.
  • Personalize therapies for conditions that previously had no known treatments.
  • Enable large-scale manufacturing in a cost-effective manner.

The Center for Regenerative Biotherapeutics is seeking to create the world's most advanced ecosystem for biomanufacturing new biotherapeutics, bringing together physicians, scientists, process development experts, high-tech facilities and industry collaborators to test and license first-of-their-kind biologics.

Read the rest of the article on the Center for Regenerative Biotherapeutics blog.


Other Mayo Clinic medical research websites:

Related articles